Cutaneous lupus erythematosus (CLE)—a common presentation of lupus erythematosus—may exist independently or as a part of the systemic manifestations of systemic lupus erythematosus. The effects of living with and treating a chronic condition such as CLE can be debilitating to a patient's health and finances. The management of patients with CLE is made particularly challenging by poor compliance, limited therapeutic options, scarcity of evidence supporting their use, and significant differences in costs of medications. Effective management of CLE should center on prevention, individualized treatment regimens, and a mutual understanding of the challenges that patients with CLE face. This article seeks to provide an overview of the efficacy, safety, and cost of therapeutic options for CLE.
Gilliam JN, Sontheimer RD. Distinctive cutaneous subsets in the spectrum of lupus erythematosus. Maryland Heights, MO: Mosby, 1981.
2.
JamesJKim-HowardXBrunerBet al.Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus2007; 16: 401–409.
3.
KuhnAAbererEBata-CsörgőZet al.S2k guideline for treatment of cutaneous lupus erythematosus–guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol2017; 31: 389–404.
4.
KleinRMoghadam-KiaSTaylorLet al.Quality of life in cutaneous lupus erythematosus. J Am Acad Dermatol2011; 64: 849–858.
5.
VasquezRWangDTranQPet al.A multicentre, cross-sectional study on quality of life in patients with cutaneous lupus erythematosus. Br J Dermatol2013; 168: 145–153.
6.
TurchettiGYazdanyJPallaIYelinEMoscaM. Systemic lupus erythematosus and the economic perspective: a systematic literature review and points to consider. Clin Exp Rheumatol2012; 30: S116.
7.
DrenkardCBaoGDennisGet al.Burden of systemic lupus erythematosus on employment and work productivity: data from a large cohort in the southeastern United States. Arthritis Care Res2014; 66: 878–887.
8.
PanopalisPYazdanyJGillisJZet al.Health care costs and costs associated with changes in work productivity among persons with systemic lupus erythematosus. Arthritis Care Res2008; 59: 1788–1795.
9.
OgunsanyaMNduagubaSBrownC. Incremental health care services and expenditures associated with depression among individuals with cutaneous lupus erythematosus (CLE). Lupus2018; 27: 1107–1115.
10.
PietteEWFoeringKPChangAYet al.The impact of smoking in cutaneous lupus erythematosus. Arch Dermatol2012; 148: 317.
11.
KuhnASiggesJBiazarCet al.Influence of smoking on disease severity and antimalarial therapy in cutaneous lupus erythematosus: analysis of 1002 patients from the EUSCLE database. Br J Dermatol2014; 171: 571–579.
12.
TeskeNMCardonZOgunsanyaMLiXAdams-HuetBChongBF. Predictors of low quality of life in patients with discoid lupus. Br J Dermatol2017; 177: e147–e149.
13.
NingWDongYSunJet al.Cigarette smoke stimulates matrix metalloproteinase-2 activity via EGR-1 in human lung fibroblasts. Am J rRespir Cell Mol Biol2007; 36: 480–490.
14.
SeagraveJBarrEBMarchTHNikulaKJ. Effects of cigarette smoke exposure and cessation on inflammatory cells and matrix metalloproteinase activity in mice. Exp Lung Res2004; 30: 1–15.
15.
KuhnABeissertS. Photosensitivity in lupus erythematosus. Autoimmunity2005; 38: 519–529.
16.
KuhnABijlM. Pathogenesis of cutaneous lupus erythematosus. Lupus2008; 17: 389–393.
17.
ZahnSGraefMPatsinakidisNet al.Ultraviolet light protection by a sunscreen prevents interferon-driven skin inflammation in cutaneous lupus erythematosus. Exp Dermatol2014; 23: 516–518.
18.
KuhnAGenschKHaustMet al.Photoprotective effects of a broad-spectrum sunscreen in ultraviolet-induced cutaneous lupus erythematosus: a randomized, vehicle-controlled, double-blind study. J Am Acad Dermatol2011; 64: 37–48.
19.
CallenJRothDMcGrathCDromgooleS. Safety and efficacy of a broad-spectrum sunscreen in patients with discoid or subacute cutaneous lupus erythematosus. Cutis1991; 47: 130–132.
20.
GutmarkELinDBernsteinIWangSChongB. Sunscreen use in patients with cutaneous lupus erythematosus. Br J Dermatol2015; 173: 831–834.
21.
CusackCDanbyCFallonJCet al.Photoprotective behaviour and sunscreen use: impact on vitamin D levels in cutaneous lupus erythematosus. Photodermatol Photoimmunol Photomed2008; 24: 260–267.
22.
KaushikALaumannANweSKwasnyMJWestDPKunduRV. Evaluation of benefit to educational material for photoprotection in those with cutaneous lupus erythematosus. J Drugs Dermatol2015; 14: 355–358.
23.
GarciaFPivelJGuerreroAet al.Phenolic components and antioxidant activity of Fernblock (R), an aqueous extract of the aerial parts of the fern Polypodium leucotomos. Methods Findings Exp Clin Pharmacol2006; 28: 157–160.
24.
GombauLGarciaFLahozAFabreMRoda-NavarroPMajanoPet al.Polypodium leucotomos extract: antioxidant activity and disposition. Toxicol In Vitro2006; 20: 464–471.
25.
BreithauptADJacobSE. Subacute cutaneous lupus erythematosus: a case report of Polypodium leucotomos as an adjuvant therapy. Cutis2012; 89: 183–184.
26.
Johal R, Leo MS, Ma B, Sivamani RK. The economic burden of sunscreen usage. Dermatol Online J 2014; 20(6): 13030/qt6v0352fw.
27.
XuSKwaMAgarwalARademakerAKunduRV. Sunscreen product performance and other determinants of consumer preferences. JAMA Dermatol2016; 152: 920–927.
RoenigkHJrMartinJEichornPGilliamJ. Discoid lupus erythematosus. Diagnostic features and evaluation of topical corticosteroid therapy. Cutis1980; 25: 281.
30.
AvgerinouGPapafragkakiDKNasiopoulouAArapakiAKatsambasAStavropoulosP. Effectiveness of topical calcineurin inhibitors as monotherapy or in combination with hydroxychloroquine in cutaneous lupus erythematosus. J Eur Acad Dermatol Venereol2012; 26: 762–767.
31.
KuhnAGenschKHaustMet al.Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double-blind, vehicle-controlled trial. J Am Acad Dermatol2011; 65: 54–64.
32.
TzungTYLiuYSChangHW. Tacrolimus vs. clobetasol propionate in the treatment of facial cutaneous lupus erythematosus: a randomized, double-blind, bilateral comparison study. Br J Dermatol2007; 156: 191–192.
33.
BarikbinBGivradSYousefiMEskandariF. Pimecrolimus 1% cream versus betamethasone 17-valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double-blind, randomized pilot study. Clin Exp Dermatol2009; 34: 776–780.
34.
Ruiz-IrastorzaGRamos-CasalsMBrito-ZeronPKhamashtaMA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis2010; 69: 20–28.
35.
ChassetFBouazizJDCostedoat-ChalumeauNFrancèsCArnaudL. Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: a systematic review and meta-analysis. Br J Dermatol2017; 177: 188–196.
36.
ChangJWerthVP. Therapeutic options for cutaneous lupus erythematosus: recent advances and future prospects. Expert Rev Clin Immunol2016; 12: 1109–1121.
37.
YokogawaNEtoHTanikawaAet al.Effects of hydroxychloroquine in patients with cutaneous lupus erythematosus: a multicenter, double-blind, randomized, parallel-group trial. Arthritis Rheumatol2017; 69: 791–799.
38.
UgarteAPortaSRíosRet al.Combined mepacrine–hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity. Lupus2018; 27: 1718–1722.
39.
MarmorMFKellnerULaiTYMellesRBMielerWF. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology2016; 123: 1386–1394.
40.
BrowningDJ. Impact of the revised American Academy of Ophthalmology guidelines regarding hydroxychloroquine screening on actual practice. Am J Ophthalmol2013; 155: 418–428.
41.
JorgeAUngCYoungLHMellesRBChoiHK. Hydroxychloroquine retinopathy—implications of research advances for rheumatology care. Nat Rev Rheumatol2018; 14: 693–703.
42.
ChassetFArnaudLCostedoat-ChalumeauNZahrNBessisDFrancèsCJ. The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): an open-label prospective pilot study. J Am Acad Dermatol2016; 74: 693–699.
43.
FrancèsCCosnesADuhautPet al.Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study. Arch Dermatol2012; 148: 479–484.
44.
Costedoat-ChalumeauNAmouraZHulotJ-Set al.Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. Ann Rheum Dis2007; 66: 821–824.
45.
Costedoat-ChalumeauNPouchotJGuettrot-ImbertGet al.Adherence to treatment in systemic lupus erythematosus patients. Best Pract Res Clin Rheumatol2013; 27: 329–340.
46.
PrestoJHejaziEWerthV. Biological therapies in the treatment of cutaneous lupus erythematosus. Lupus2017; 26: 115–118.
47.
WenzelJLandmannAVorwerkGKuhnA. High expression of B lymphocyte stimulator in lesional keratinocytes of patients with cutaneous lupus erythematosus. Exp Dermatol2018; 27: 95–97.
48.
ManziSSánchez-GuerreroJMerrillJTet al.Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis2012; 71: 1833–1838.
49.
Hui-YuenJSReddyATaylorJet al.Safety and efficacy of belimumab to treat systemic lupus erythematosus in academic clinical practices. J Rheumatol2015; 42: 2288–2295.
50.
CollinsCDall'EraMKanHet al.Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA. Lupus Sci Med2016; 3: e000118.
51.
VashishtPBorghoffKO'DellJHearth-HolmesM. Belimumab for the treatment of recalcitrant cutaneous lupus. Lupus2017; 26: 857–864.
52.
Husein-ElAhmedHCallejas-RubioJLRios-FernandezROrtego-CentenoN. Refractory subacute cutaneous lupus erythematous responding to a single course of belimumab: a new anti-BLyS human monoclonal antibody. Indian J Dermatol Venereol Leprol2014; 80: 477.
53.
Raymond LamoreSPIIIPatelKHilasO. Belimumab (benlysta): a breakthrough therapy for systemic lupus erythematosus. Pharm Ther2012; 37: 212.
54.
NutanFOrtega-LoayzaAG. Cutaneous lupus: a brief review of old and new medical therapeutic options. J Invest Dermatol Symp Proc2017; 18: S64–S68.
